How Pariglasgene Brecaparvovec Works: The First Gene Therapy for GSD1a Explained

Every three to four hours, day and night. That's how often people with Glycogen Storage Disease Type 1a have had to eat raw cornstarch just to keep their blood sugar from crashing. In August 2026, that changed. The FDA approved pariglasgene brecaparvovec (Genglycos) — the first gene therapy for GSDIa, and the first treatment that targets the disease at its actual genetic root. In this video, we break down exactly how it works: the missing G6Pase enzyme behind GSDIa, how an AAV8 viral vector delivers a working gene straight to liver cells, and what the clinical trial data actually show. Disclaimer: This YouTube channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for healthcare professional advice. Please consult a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements about specific products are not to diagnose, treat, cure, or prevent disease. References: 1. Hannah, W. B., Derks, T. G., Drumm, M. L., Grünert, S. C., Kishnani, P. S., & Vissing, J. (2023). Glycogen storage diseases. Nature Reviews Disease Primers, 9(1), 46. 2. https://www.fda.gov/news-events/press... 3. Nana M, Anastasopoulou C, Parikh NS, et al. Glycogen Storage Disease Type I. [Updated 2025 Apr 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NB... 4. Gümüş E, Özen H. Glycogen storage diseases: An update. World J Gastroenterol. 2023 Jul 7;29(25):3932-3963. doi: 10.3748/wjg.v29.i25.3932. PMID: 37476587; PMCID: PMC10354582. 5. https://pharmacally.com/genglycos-fda... 6. https://www.pharmacytimes.com/view/fd... 7. https://synapse.patsnap.com/article/w... 8. Weinstein, D. A., Derks, T. G., Rodriguez‐Buritica, D. F., Ahmad, A., Couce, M. L., Mitchell, J. J., ... & Crombez, E. (2025). Safety and Efficacy of DTX401, an AAV8‐Mediated Liver‐Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a (GSDIa). Journal of inherited metabolic disease, 48(2), e70014. #GeneTherapy #GSD1a #GlycogenStorageDisease #RareDisease #VonGierkeDisease #Genglycos #AAV8 #FDAApproval #MedicalEducation #Pharmacology #RareDiseaseAwareness #GeneTherapyBreakthrough #LiverDisease #Hypoglycemia #MetabolicDisorder #ClinicalTrial #Biotech #PharmaNews #HealthEducation #ScienceExplained #PharmacyEducation